Rein Therapeutics
RNTX
23 hedge funds and large institutions have $12.3M invested in Rein Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.
971% more capital invested
Capital invested by funds: $1.15M → $12.3M (+$11.1M)
1.7% more ownership
Funds ownership: 0.46% → 2.16% (+1.7%)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.04M |
| 2 |
Jennison Associates
New York
|
+$2.75M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$155K |
| 4 |
Bank of New York Mellon
New York
|
+$124K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$88.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$108K |
| 2 |
Renaissance Technologies
New York
|
-$89.8K |
| 3 |
Millennium Management
New York
|
-$37K |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$36K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$18.8K |
RNTX Hedge Fund Activity: Q1 2019 in Review
23 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2019, worth a combined $12.3M — up 971% from $1.15M a quarter earlier.
Fund positioning in RNTX was balanced in Q1 2019: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.04M. The largest seller was Deutsche Bank, exiting entirely with an estimated $108K sold.
- 23 institutional investors held Rein Therapeutics (RNTX) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $12.3M of Rein Therapeutics stock for Q1 2019, up 971% quarter-over-quarter.
- 7 funds opened new Rein Therapeutics positions in Q1 2019 and 7 closed out, a net change of 0 holders.
- The largest Rein Therapeutics buyer in Q1 2019 was Armistice Capital, an estimated $5.04M added.
- The largest Rein Therapeutics seller in Q1 2019 was Deutsche Bank, an estimated $108K sold.
Based on aggregated 13F filings for Q1 2019.